November 6, 2018 – By Theresa McIntyre
In November, 13 UroGen Pharma Ltd. is expected. (NASDAQ: URGN) performance report according to RTT. Analysts have expectations of the share company's earnings per share of $ -1.08. It is 5,300.00% compared with last year's earnings per share of -0.02 SEK. After $ -1.14 EPS report last quarter, Wall Street now forecasts -5.26% EPS growth in UroGen Pharma Ltd. Ticker shares affected 44.43 USD during the last trading period after 0.98% change. At the same time, UroGen Pharma Ltd. is increasing. after 53.87% change last November 6, 2017. URGN has 14,940 shares volume. The stock exceeded the S & P500 by 38.25%.
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is valued at $ 705.70 million. The company's main product candidates, MitoGel and VesiGel are formulations of chemotherapeutic drug Mitomycin C, a generic drug currently used off-label for the treatment of urothelial cancer only in a water formulation as adjuvant or complementary post-operative treatment. it has a negative result. The company develops its product candidates as chemotherapeutic agents, designed to remove tumors in non-surgical procedures to treat multiple forms of non-muscular invasive urothelial cancer including low upper urethral carcinoma in the upper part and low-grade bladder cancer.
There is a significant UroGen Pharma Ltd. (NASDAQ: URGN) news announced by Globenewswire.com. It's an article titled: "Market Development Against New Normal in UGGEN PHARMA, Cimarex Energy, Boingo Wireless, TransCanada …" October 24, 2018.